Skip to main content
Fig. 6 | BMC Proceedings

Fig. 6

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 6

The algorithm shows the steps and scenarios to reduce the pill burden with the CNIC-Polypill in patients treated for chronic CVD. Note: *Dose adjusted to previous ACEI/ARB dose and renal function. $Use only if the patient does not develop side effects to atorvastatin 80 mg (or equivalent doses of another statin).†If the combination is available. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; AT, atorvastatin; BP, blood pressure; CCB, calcium channel blocker; CCS, chronic coronary syndrome; EZE, ezetimibe; FDC, fixed-dose combination; LDL-c, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; RAM, ramipril; Tx, treatment. Source: Grigorian-Shamagian et al. Front Cardiovasc Med. 2021;8:663,361 [12]. Reproduced with permission

Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us